Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.816
+0.026 (3.29%)
Mar 5, 2026, 12:15 PM EST - Market open
Cytosorbents Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cytosorbents stock have an average target of 5.38, with a low estimate of 0.75 and a high estimate of 10. The average target predicts an increase of 559.31% from the current stock price of 0.82.
Analyst Consensus: Buy
* Price targets were last updated on Jan 12, 2026.
Analyst Ratings
The average analyst rating for Cytosorbents stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,125.49% | Jan 12, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,125.49% | Dec 16, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,125.49% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.75 | Hold | Maintains | $1 → $0.75 | -8.09% | Nov 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,125.49% | Sep 16, 2025 |
Financial Forecast
Revenue This Year
38.19M
from 35.59M
Increased by 7.29%
Revenue Next Year
41.59M
from 38.19M
Increased by 8.91%
EPS This Year
-0.17
from -0.38
EPS Next Year
-2.84
from -0.17
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.1M | 43.2M | ||||
| Avg | 38.2M | 41.6M | ||||
| Low | 36.3M | 39.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 12.6% | 13.2% | ||||
| Avg | 7.3% | 8.9% | ||||
| Low | 2.0% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.11 | -0.16 | |
| Avg | -0.17 | -2.84 | |
| Low | -0.22 | -7.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.